Radnor, Pennsylvania, Oct 12, 2021 (Newsfile Corp via COMTEX) -- Radnor, Pennsylvania--(Newsfile Corp. - October 12, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Annovis Bio, Inc. /zigman2/quotes/216213707/composite ANVS +5.98% ("Annovis") investors that a securities fraud class action lawsuit has been on behalf of those who purchased or acquired Annovis securities betweeen May 21, 2021 and July 28, 2021 , inclusive (the "Class Period").
TO SUBMIT YOUR ANNOVIS LOSSES
LEAD PLAINTIFF DEADLINE : October 18, 2021
CLASS PERIOD: May 21, 2021 through July 28, 2021
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
James Maro, Esq. (484) 270-1453 or Toll free (844) 887-9500 or via email at firstname.lastname@example.org
ANNOVIS' ALLEGED MISCONDUCT
Annovis is a clinical stage pharmaceutical company that is developing therapies addressing neurodegeneration, such as Alzheimer's disease ("AD"), Parkinson's disease, and Alzheimer's disease in Down syndrome. Its lead compound is ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration.
The complaint alleges that throughout the Class Period, the defendants failed to disclose to investors that: (1) Annovis's ANVS401 did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, the defendants' positive statements about Annovis's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT CAN I DO?
Annovis investors may, no later than October 18, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer& Check, LLP encourages Annovis investors who have suffered significant losses to contact the firm directly to acquire more information.
WHO CAN BE A LEAD PLAINTIFF?
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Because Kessler Topaz Meltzer & Check, LLP prosecutes class actions on a contingency fee basis, there are no out-of-pocket fees or expenses paid by the lead plaintiff, regardless of the outcome of the case. If we are successful in obtaining a recovery for the class, we will apply to the court for a fee that fairly represents the work performed and risk assumed. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
CLICK HERE TO SIGN UP FOR THE CASE
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. At the end of the day, we have succeeded if the bad guys pay up, and if you recover your assets. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99411
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.
copyright (c) newsfile corp. 2021. all rights reserved